Several active compounds in QFY showed interactions with other AD-relevant mediators (e.g., BACE1, APP, and SNCA), cholinergic neurotransmission (e.g., ACHE, CHRM1, CHRNA4, and CHRNB2), and inflammation (e.g., COX-2, eNOS, and iNOS). This evidence concerns the gene SNCA and Alzheimer disease.